RA Capital Management 13F holdings, Q3 2011
Holdings as of September 30, 2011 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 20 US equity positions worth $90.3m in its Q3 2011 13F filing. The largest position was SEQUENOM INC at 14.9% of the reported book, followed by COLUMBIA LABS INC and ARTHROCARE CORP. Against the Q2 2011 filing, it opened 8 new positions, added to 6 and reduced 4 among the top 20 holdings.
What did RA Capital Management own in Q3 2011? Top 20 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2011 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 14.9% | $13.4m | 2,637,067 | 25% | added | |
| 2 | COLUMBIA LABS INC | 9.0% | $8.1m | 4,177,159 | 45% | added | |
| 3 | ARTHROCARE CORP | 8.1% | $7.3m | 254,749 | -37% | reduced | |
| 4 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 7.9% | $7.1m | 1,437,320 | 277% | added |
| 5 | VENTRUS BIOSCIENCES INC | 7.1% | $6.4m | 705,450 | – | new | |
| 6 | DERMA SCIENCES INC | 6.9% | $6.2m | 796,212 | 3% | added | |
| 7 | PHARMASSET INC | 6.4% | $5.7m | 69,600 | 39% | added | |
| 8 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 6.3% | $5.7m | 5,269,999 | 0% | held |
| 9 | ALEXZA PHARMACEUTICALS INC | 4.7% | $4.2m | 3,905,653 | -0% | held | |
| 10 | ENDOCYTE INC | 4.6% | $4.2m | 393,354 | – | new | |
| 11 | RAPTOR PHARMACEUTICAL CORP | 4.5% | $4.1m | 900,000 | – | new | |
| 12 | TRIMERIS INC | 4.4% | $3.9m | 1,559,106 | – | new | |
| 13 | ENZB ENZO BIOCHEM INC | 3.9% | $3.6m | 1,383,830 | 64% | added | |
| 14 | ANACOR PHARMACEUTICALS INC | 2.9% | $2.6m | 462,100 | -14% | reduced | |
| 15 | FURIEX PHARMACEUTICALS INC | 2.3% | $2.1m | 146,101 | -34% | reduced | |
| 16 | ANTHERA PHARMACEUTICALS INC | 1.9% | $1.8m | 368,807 | – | new | |
| 17 | SYNTA PHARMACEUTICALS CORP | 1.7% | $1.5m | 465,284 | – | new | |
| 18 | TEARLAB CORP | 1.4% | $1.2m | 1,383,700 | – | new | |
| 19 | TENGION INC | 0.6% | $572.0k | 1,060,070 | -49% | reduced | |
| 20 | SUNESIS PHARMACEUTICALS INC | 0.6% | $510.0k | 414,793 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.